DUBLIN–(BUSINESS WIRE)–The “Global Actinic Keratosis Treatment Market 2020-2026” report has been added to ResearchAndMarkets.com’s offering.
The actinic keratosis treatment market is anticipated to showcase a considerable growth rate during the forecast period. The rising prevalence and incidence of actinic keratosis treatment along with the rising development of novel approaches for the treatment of actinic keratosis is anticipated to be a key factor contributing to the growth of the market.
The actinic keratosis treatment market is segmented based on type, and end-user. Based on the type, the market is segmented into medication, therapy, and other (combination therapy). Medication to showcase considerable growth based on treatment type. The growing FDA approval for the new drugs to treat actinic keratosis is anticipated to drive the growth of this market segment. Based on medication, the market is segmented into fluorouracil, imiquimod, ingenol mebutate, others. Based on therapy, the market is segmented into photodynamic therapy and LASER surgery. Based on end-user, the market is segmented into hospitals & oncology centers, and dermatology clinics.
Geographically, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America is anticipated to hold a considerable market share in the actinic keratosis treatment market due to the high awareness of the drugs for the treatment of actinic keratosis treatment in the region. Asia-Pacific is the fastest-growing region in the market. The increasing prevalence of skin disorders in the emerging economies of Asia-Pacific is a key factor contributing to the growth of the market in the region.
Companies Mentioned
- 3M Co.
- Alma Lasers, Inc.
- Almirall, S.A.
- Bausch Health Companies Inc.
- Biofrontera AG
- BioLineRx, Ltd.
- Cipher Pharmaceuticals, Inc.
- Galderma S.A.
- Hill Dermaceuticals, Inc.
- LEO Pharma A/S
- Mylan N.V.
- Stanford Chemicals Company
- Sun Pharmaceutical Industries, Ltd.
- Teva Pharmaceutical Industries, Ltd.
- Valeant Pharmaceuticals, Inc.
Market Segmentation:
1. Global Actinic Keratosis Treatment Market Research and Analysis by Type
2. Global Actinic Keratosis Treatment Market Research and Analysis by End-User
The Report Covers:
- Comprehensive research methodology of the global actinic keratosis treatment market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global actinic keratosis treatment market.
- Insights about market determinants that are stimulating the global actinic keratosis treatment market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Key Topics Covered:
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. LEO Pharma A/S
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Biofrontera AG
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Sun Pharmaceuticals Industries, Ltd.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. 3M Co.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Galderma S.A.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Actinic Keratosis Treatment Market by Type
5.1.1. Medication
5.1.1.1. Fluorouracil
5.1.1.2. Imiquimod
5.1.1.3. Ingenol Mebutate
5.1.1.4. Others
5.1.2. Therapy
5.1.2.1. Photodynamic Therapy
5.1.2.2. Laser Surgery
5.1.3. Others (Combination Therapy)
5.2. Global Actinic Keratosis Treatment Market by End-User
5.2.1. Hospitals & Oncology Centers
5.2.2. Dermatology Clinics
6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/qpeip7
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900